Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing Program

Publication Details

Circulation: Genomic and Precision Medicine

August 2021

Access Here

Author(s)

Barry H Trachtenberg¹, Sachin K Shah², Robert L Nussbaum³, Sara L Bristow³, Ruthvik Malladi², Matteo Vatta³

Affiliations

¹Methodist DeBakey Heart and Vascular Center, Houston, TX (B.H.T.);²Alnylam Pharmaceuticals, Cambridge, MA (S.K.S., R.M.); ³Invitae, San Francisco, CA (R.L.N., S.L.B., M.V.)